Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Genetic toxicity: in vivo

Currently viewing:

Administrative data

Endpoint:
in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
guideline study without detailed documentation

Data source

Reference
Reference Type:
other company data
Title:
Unnamed
Year:
2014
Report date:
2003

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
GLP compliance:
yes
Type of assay:
other: micronuclei in erythrocytes of the bone marrow

Test material

Specific details on test material used for the study:
Study performed using the active pharmaceutical ingredient Liraglutide as test substance

Test animals

Species:
rat
Strain:
other: Crl:CD BR(CD)
Details on species / strain selection:
Not specified
Sex:
male/female
Details on test animals or test system and environmental conditions:
Not specified

Administration / exposure

Route of administration:
subcutaneous
Vehicle:
Phosphate buffer
Details on exposure:
Four groups, each of seven male rats were administered 0, 7.5, 15 and 30 mg liraglutide/kg/day on four consecutive days. Additionally, one vehicle, one untreated, and one positive control (Cyclophoschamide 40mg/kg single dose) group were administrated.
Duration of treatment / exposure:
-One daily administration for four consecutive days for the treated, untreated, and vehicle control group.
-The positive control group was given a subcutaneous injection of Cyclophoschamide.
Frequency of treatment:
Four (one subcutaneous injection per day)
Post exposure period:
Animals were sacrificed 24 hours after the last treatment.
Doses / concentrationsopen allclose all
Dose / conc.:
7.5 mg/kg bw/day (actual dose received)
Dose / conc.:
15 mg/kg bw/day (actual dose received)
Dose / conc.:
30 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
7 male rats per dose
Control animals:
yes, concurrent vehicle
Positive control(s):
Yes, Cyclophoschamide.

Examinations

Tissues and cell types examined:
Polychromatic erythrocytes (PCE) from bone marrow
Details of tissue and slide preparation:
Not specified
Evaluation criteria:
Micronucleus frequency was estimate din 1000 PCE per animal
Statistics:
Not specified

Results and discussion

Test results
Key result
Sex:
male
Genotoxicity:
negative
Toxicity:
yes
Remarks:
reduction in weight gain and in the ratio between polychromatic and normochromatic erythrocytes compared to controls.
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Additional information on results:
Slides from all dose groups were analysed and micronucleus frequency estimated in 1000 PCE per animal. All positive control animals exhibited increased numbers of micronucleated PCE such that the micronucleus frequency in the positive control group was significantly greater than in concurrent controls.

Mice treated with all three doses levels of Liraglutide showed a reduction in weight gain relative to control, and a reduction in group mean ratios of PCE to NCE compared to control group. Furthermore, the group mean frequencies of micronucleated erythrocytes were similar to those of the controls at all dose levels.

Liraglutide did not induce micronuclei in the polychromatic erythrocytes of the bone marrow of treated rats up to 30 mg/kg, a dose at which bone marrow toxicity was seen.

Applicant's summary and conclusion

Conclusions:
Determination of micronuclei in the bone marrow of Liraglutide treated rats was conducted in accordance to OECD Test Guideline 474. The test compound did not induce micronuclei in polychromatic erythrocytes of the bone marrow of rats treated up to 30 mg/kg/day, a dose at which bone marrow toxicity were seen.
Executive summary:

Determination of micronuclei in the bone marrow of Liraglutide treated rats was conducted in accordance to OECD Test Guideline 474. Liraglutide was assayed for its potential to induce micronuclei in the bone marrow of polychromatic erythrocytes (PCE) of male Crl:CD®BR(CD) rats after s.c. injection. Four groups, each of seven male rats were administered 0, 7.5, 15 and 30 mg liraglutide/kg/day on four consecutive days. The rats were killed 24 hours after the final administration and bone marrow was sampled. All three dose levels caused a reduction in weight gain relative to controls and a reduction in the ratio between polychromatic and normochromatic erythrocytes. The group mean frequencies of micronucleated erythrocytes were similar to those of the controls at all dose levels. Liraglutide did not induce micronuclei in the polychromatic erythrocytes of the bone marrow of treated rats up to 30 mg/kg, a dose at which bone marrow toxicity was seen.